Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Journal of Clinical Pharmacy and Pharmaceutical Science
Fef Rukminingsih
Politeknik Katolik Mangunwijaya Semarang
Medicine & Pharmacology

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
BIAYA MEDIK LANGSUNG PASIEN STROKE NON-HEMORAGIK KELAS PERAWATAN 3 RSUD K.R.M.T WONGSONEGORO SEMARANG Hanik Utaminingrum; Fef Rukminingsih
Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Vol 5 No 1 (2020): JIIS
Publisher : Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (188.256 KB) | DOI: 10.36387/jiis.v5i1.413

Abstract

The most common stroke in Indonesia is non-hemorrhagic stroke (SNH), which occurs in 85-87% of all stroke cases. Stroke requires expensive costs because the process of treating stroke patients is done in a long time and routine. SNH patients who go to K.R.M.T Wongsonegoro Hospital Semarang every year increase in number. This study aims to determine the amount of direct medical costs for treatment class 3 SNH patients at K.R.M.T Wongsonegoro Hospital Semarang and their compliance with Indonesian Case Based Groups (INA-CBG) rates. This study is a pharmacoeconomic study with a hospital perspective on direct medical costs using retrospective data for the October-December 2018 period. The object of this study is the medical record and billing data from the Hospital Information and Management System SNH patients participating in the National Health Insurance treated in treatment class 3. Based on the results of medical record tracking and billing data for SNH patients, 64 patients were known. The number of female patients was 41 people (64.06%). Most of the patients (93.75%) were over 45 years old. A total of 27 patients included in the category of mild SNH and 37 patients in the category of moderate SNH. The average direct medical cost for SNH patients in the mild category is IDR 3,005,019 ± 1,010,931, - and the compliance with INA-CBG’s tariff was 92.59%. The average direct medical cost for SNH patients in the moderate category is IDR 3,602,846 ± 1,259,001 and the compliance with INA-CBG rates of 94.59%.
EVALUASI BIAYA KEMOTERAPI PASIEN EARLY BREAST CANCER DI RSUD TUGUREJO SEMARANG PERIODE JULI-DESEMBER 2018 Wilis Rakhmadhanti; Fef Rukminingsih
Journal Clinical Pharmacy and Pharmaceutical Science Vol. 1 No. 1 (2022): April: Journal of Clinical Pharmacy and Pharmaceutical Science
Publisher : Prodi D3 Farmasi Politeknik Katolik Mangunwijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.61740/jcp2s.v1i1.1

Abstract

Early breast cancer (EBC) is defined as with or without in a breast cancer, but it has not metastasized to wider tissue. Chemotherapy expense  has 59% portion of the total cost of cander patients at the hospital. There were 137 EBC patients visit during January-March 2018 conducted at Tugurejo Regional Hospital Semarang. Therefore, research is needed to evaluate the cost of chemotherapy in EBC patient in Tugurejo  Hospital Semarang. This study was an observational descriptive study with a cross sectional study design. Data sources were gained from Medical Record (MR) data and billing / billing data for National Health Insurance (JKN) participant patients with an EBC diagnosis undergoing chemotherapy at Tugurejo Hospital Semarang in the period July-December 2018. The inclusion criteria for this study was JKN patients with EBC diagnosis age 17 -65 years who did chemotherapy at Tugurejo General Hospital Semarang in the period July-December 2018. Data was processed qualitatively and quantitatively. The results of evaluation of  the cost of chemotherapy for EBC patients at Tugurejo Hospital Semarang in the period July-December 2018 were done with the regimen Doxorubicin-Doxetacel-Fluorouracil (AT-F) Rp 3.683.388,00 ± 193.960, Doxetacel-Epirubicin-Fluorouracil (TE-F) Rp 4.342.914 00 ± 37.614, Fluorouracil-Epirubicin-Cyclofosphamid (FEC) Rp 2.929.464,00 ± 193.960, Fluorouracil-Doxorubicin-Cyclofosphamid (FAC) amounting to Rp2.471.671,00 ± 193.960.  
Co-Authors Hanik Utaminingrum Wilis Rakhmadhanti